 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Ibrutinib (ibrutinib) combined with Rituximab (rituximab) in the treatment of indolent mantle cell lymphoma (IMCL-2015)

J Clin Oncol: Ibrutinib (ibrutinib) combined with Rituximab (rituximab) in the treatment of indolent mantle cell lymphoma (IMCL-2015)

 Last Update: 2022-01-23
 Source: Internet
 Author: User

Tags

86 blood sugar

water cell

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, the Journal of Clinical Oncology published the results of a phase II study IMCL-2015 from Spain , which mainly evaluated the use of Ibrutinib (ibrutinib) in combination with Rituximab in patients with clinically indolent mantle cell lymphoma (MCL).
(Rituximab) treatment efficacy
.

lymphoma

The IMCL-2015 study (NCT02682641) is a multicenter, single-arm, open-label, phase II study conducted at 12 centers in Spain
.

The primary endpoint was the complete response (CR) rate achieved after 12 cycles according to Lugano criteria

The IMCL-2015 study (NCT02682641) is a multicenter, single-arm, open-label, phase II study conducted at 12 centers in Spain

The study included 50 patients with MCL (66% male; mean age 65 years)

Efficacy assessment

After a median follow-up of 36 months, the 36-month progression-free survival (PFS) rate was 93% (95% CI, 86 - 100), with only MIPI and TP53 mutational status having a significant effect on PFS, in molecular subtypes ( nnMCL vs cMCL) and genome complexity
.

prognostic analysis

The median PFS of patients with TP53 mutation was 38.
5 months (95% CI, 37-39), while the median PFS of patients with TP53 wild type had not been reached (P<0.
0001); similarly, the median OS of patients with TP53 mutation was higher than that of TP53 wild type Patients were significantly shorter (38.
5 months; 95% CI, 37-39 vs not reached, P=0.
0002)
.

The median PFS of patients with TP53 mutation was 38.

The most common treatment-related AEs were diarrhea (38%), neutropenia (36%), fatigue (32%), upper respiratory tract infection (24%), nausea (22%), and arterial hypertension (20%)

AEs

In conclusion, the study shows that Ibrutinib (ibrutinib) combined with Rituximab (rituximab) is effective in the treatment of indolent mantle cell lymphoma
.

Studies have shown that Ibrutinib (ibrutinib) combined with Rituximab (rituximab) is effective in the treatment of indolent mantle cell lymphoma

Original source:

Giné E, de la Cruz F, Jiménez Ubieto A, López Jimenez J, Martín García-Sancho A, Terol MJ, González Barca E, Casanova M, de la Fuente A, Marín-Niebla A, Muntañola A, González-López TJ, Aymerich M, Setoain X, Cortés-Romera M, Rotger A, Rodríguez S, Medina Herrera A, García Sanz R, Nadeu F, Beà S, Campo E, López-Guillermo A.
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
J Clin Oncol.
2022 Jan 14:JCO2102321.
doi: 10.
1200/JCO.
21.
02321.
Epub ahead of print.
PMID: 35030036.
leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.